AVALOX sol perf 400 mg/250ml fl 250 ml
7680582570110
CH-58257
J01MA14
08.01.8.
Reimbursement limitations:
AVALOX
L'administration parentérale doit être réservée aux patients chez lesquels un traitement oral n'est pas indiqué.
1 / 3
google
Details
- Product number
- 5825701
- CPT
- -
- Packaging group
- 250
- Unit
- ml
- Composition
- moxifloxacinum 400 mg ut moxifloxacini hydrochloridum 436 mg, natrii chloridum, acidum hydrochloridum q.s. ad pH, natrii hydroxidum q.s. ad pH, aqua ad iniectabile ad solutionem pro 250 ml, natrium 813 mg.
Articles (1)
Avalox, Infusionslösung
Infusionslösung
250
Official Swissmedic V2 data
Additional information from the official database
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
400.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
436.0 MG | Substance | WIZUS |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
813.0 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 65.95
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/02/2013
Authorization holder
Bayer (Schweiz) AG
8045 Zürich
Authorization information
- Swissmedic authorization number
- 58257
- Drug name
- Avalox, Infusionslösung
- Galenic form
- LSPA
- ATC Code
- J01MA14
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 20/11/2009
- Authorization expiration date
- 31/12/9999
- IT number
- 08.01.8.
- Domain
- Human medicine
Packaging details
- Description (FR)
- AVALOX sol perf 400 mg/250ml fl 250 ml
- Description (DE)
- AVALOX Inf Lös 400 mg/250ml Fl 250 ml
- Market launch
- 20/11/2009
- Narcotic (BTM)
- No